June 4: The Week in Cancer News
A targeted therapy improves disease-free survival when given to people with certain hereditary mutations after breast cancer surgery, and more news of the week from Cancer Today.
Progress Against Cancer
A targeted therapy improves disease-free survival when given to people with certain hereditary mutations after breast cancer surgery, and more news of the week from Cancer Today.
A study finds that many people with solid tumors mount an antibody response following COVID-19 vaccination, and more news of the week from Cancer Today.
Melanoma is an aggressive form of skin cancer. While it is less common than skin cancers like basal cell carcinoma or squamous cell carcinoma, it is much more deadly due to its tendency to...
The U.S. Preventive Services Task Force lowers its recommended age to begin colorectal cancer screening to 45, and more news of the week from Cancer Today.
Study suggests ovarian cancer screening does not reduce mortality, and more news of the week from Cancer Today.
Since 2014, the American Association for Cancer Research (AACR) has invited early-career investigators to apply to the NextGen Stars program, which provides awardees the opportunity to present their research on a global stage at the AACR Annual Meeting. The enhanced visibility granted by the NextGen Stars program has...
A Food and Drug Administration panel recommends withdrawing approvals for two treatment indications for immunotherapy drugs, and more news of the week from Cancer Today.
Many patients facing a cancer diagnosis ask their doctors a simple question: “What should I eat?” That elemental question has perplexed scientists for centuries. In a stirring discussion during the Opening Plenary session of...
President Biden resurfaces a proposal for a new health care agency, and more news of the week from Cancer Today.
Scientists discussed the mechanisms of chemotherapy-related cognitive impairment at a session dedicated to symptom science at the AACR Annual Meeting 2021.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More